-
公开(公告)号：US11951133B2
公开(公告)日：2024-04-09
申请号：US17864307
申请日：2022-07-13
发明人： Arthur T. Sands , Neil F. Bence , Christoph W. Zapf , Frederick Cohen , Chenbo Wang , Thomas Cummins , Hiroko Tanaka , Hunter Shunatona , Mario Cardozo , Dahlia Weiss , Jennifa Gosling
IPC分类号： A61K35/17 , A61K31/438 , A61K31/454 , A61K31/4545 , A61K33/243 , A61K35/761 , A61K35/763 , A61K35/768 , A61K38/19 , A61K39/00 , A61K39/39 , A61K39/395 , A61K45/06 , A61N5/10 , A61P35/00 , C07D401/14 , C07D405/14 , C07D471/04 , C07D491/107 , C07F5/02 , C12N5/0783
CPC分类号： A61K35/17 , A61K31/438 , A61K31/454 , A61K31/4545 , A61K33/243 , A61K35/761 , A61K35/763 , A61K35/768 , A61K38/193 , A61K39/0011 , A61K39/39 , A61K39/3955 , A61K45/06 , A61N5/1001 , A61N5/1077 , A61P35/00 , C07D401/14 , C07D405/14 , C07D471/04 , C07D491/107 , C07F5/022 , C12N5/0636 , A61K2039/5152 , C12N2501/2302 , C12N2501/998 , C12N2501/999
摘要： Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.
-
公开(公告)号：US20230150991A1
公开(公告)日：2023-05-18
申请号：US17853904
申请日：2022-06-29
发明人： Arthur T. SANDS , Neil F. Bence , Christoph W. Zapf , Frederick Cohen , Chenbo Wang , Thomas Cummins , Hiroko Tanaka , Hunter Shunatona , Mario Cardozo , Dahlia Weiss , Jennifa Gosling
IPC分类号： C07D413/14 , C07D401/14 , C07D403/10 , C07D403/12 , C07D405/14 , C07D471/04
CPC分类号： C07D413/14 , C07D401/14 , C07D403/10 , C07D403/12 , C07D405/14 , C07D471/04
摘要： Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.
-
公开(公告)号：US11464802B2
公开(公告)日：2022-10-11
申请号：US16844953
申请日：2020-04-09
发明人： Arthur T. Sands , Neil F. Bence , Christoph W. Zapf , Frederick Cohen , Chenbo Wang , Thomas Cummins , Hiroko Tanaka , Hunter Shunatona , Mario Cardozo , Dahlia Weiss , Jennifa Gosling
IPC分类号： A61K35/17 , A61P35/00 , A61K33/243 , A61K31/438 , A61K31/454 , A61K31/4545 , A61K35/761 , A61K35/763 , A61K35/768 , A61K38/19 , A61K39/00 , A61K39/39 , A61K39/395 , A61K45/06 , A61N5/10 , C07D401/14 , C07D405/14 , C07D471/04 , C07D491/107 , C07F5/02 , C12N5/0783
摘要： Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.
-
公开(公告)号：US20200323904A1
公开(公告)日：2020-10-15
申请号：US16844953
申请日：2020-04-09
发明人： Arthur T. Sands , Neil F. Bence , Christoph W. Zapf , Frederick Cohen , Chenbo Wang , Thomas Cummins , Hiroko Tanaka , Hunter Shunatona , Mario Cardozo , Dahlia Weiss
IPC分类号： A61K35/17 , A61K39/395 , A61K45/06 , A61K33/243 , A61K39/00 , A61K39/39 , A61K35/763 , A61K38/19 , A61K35/761 , A61K35/768 , C07D405/14 , A61K31/454 , A61K31/438 , C07D491/107 , C07D401/14 , A61K31/4545 , C07D471/04 , C07F5/02 , A61P35/00 , C12N5/0783 , A61N5/10
摘要： Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.
-
公开(公告)号：US12091426B2
公开(公告)日：2024-09-17
申请号：US18054118
申请日：2022-11-09
发明人： John Buell , Frederick Cohen , Ryan Pemberton , Hunter P. Shunatona , Lan Wang , Mark Edward Zak
IPC分类号： C07D519/00
CPC分类号： C07D519/00
摘要： The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteasome pathway, and method for treating diseases modulated by HPK1.
-
公开(公告)号：US20240293458A1
公开(公告)日：2024-09-05
申请号：US18443228
申请日：2024-02-15
发明人： Arthur T. SANDS , Neil F. Bence , Christoph W. Zapf , Frederick Cohen , Chenbo Wang , Thomas Cummins , Hiroko Tanaka , Hunter Shunatona , Mario Cardozo , Dahlia Weiss , Jennifa Gosling
IPC分类号： A61K35/17 , A61K31/438 , A61K31/454 , A61K31/4545 , A61K33/243 , A61K35/761 , A61K35/763 , A61K35/768 , A61K38/19 , A61K39/00 , A61K39/39 , A61K39/395 , A61K45/06 , A61N5/10 , A61P35/00 , C07D401/14 , C07D405/14 , C07D471/04 , C07D491/107 , C07F5/02 , C12N5/0783
CPC分类号： A61K35/17 , A61K31/438 , A61K31/454 , A61K31/4545 , A61K33/243 , A61K35/761 , A61K35/763 , A61K35/768 , A61K38/193 , A61K39/0011 , A61K39/39 , A61K39/3955 , A61K45/06 , A61N5/1001 , A61N5/1077 , A61P35/00 , C07D401/14 , C07D405/14 , C07D471/04 , C07D491/107 , C07F5/022 , C12N5/0636 , A61K2039/5152 , C12N2501/2302 , C12N2501/998 , C12N2501/999
摘要： Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.
-
公开(公告)号：US12049471B2
公开(公告)日：2024-07-30
申请号：US18068195
申请日：2022-12-19
发明人： Arthur T. Sands , Neil F. Bence , Christoph W. Zapf , Frederick Cohen , Chenbo Wang , Thomas Cummins , Hiroko Tanaka , Hunter Shunatona , Mario Cardozo , Dahlia Weiss , Jennifa Gosling
IPC分类号： C07D498/08 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D413/14 , C07D471/04 , C07D491/08
CPC分类号： C07D498/08 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D413/14 , C07D471/04 , C07D491/08
摘要： Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.
-
8.发明公开公开(公告)号：US20240018162A1
公开(公告)日：2024-01-18
申请号：US18054118
申请日：2022-11-09
发明人： John Buell , Frederick Cohen , Ryan Pemberton , Hunter P. Shunatona , Lan Wang , Mark Edward Zak
IPC分类号： C07D519/00
CPC分类号： C07D519/00
摘要： The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteasome pathway, and method for treating diseases modulated by HPK1.
-
公开(公告)号：US11530229B2
公开(公告)日：2022-12-20
申请号：US16875917
申请日：2020-05-15
发明人： Arthur T. Sands , Neil F. Bence , Christoph W. Zapf , Frederick Cohen , Chenbo Wang , Thomas Cummins , Hiroko Tanaka , Hunter Shunatona , Mario Cardozo , Dahlia Weiss , Jennifa Gosling
IPC分类号： C07D498/08 , C07D403/12 , C07D403/14 , C07D413/14 , C07D471/04
摘要： Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.026 秒)
